Lushang Freda PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 6/6
Lushang Freda PharmaceuticalLtd has a total shareholder equity of CN¥4.8B and total debt of CN¥649.4M, which brings its debt-to-equity ratio to 13.7%. Its total assets and total liabilities are CN¥6.4B and CN¥1.7B respectively. Lushang Freda PharmaceuticalLtd's EBIT is CN¥187.9M making its interest coverage ratio -3.6. It has cash and short-term investments of CN¥3.2B.
Key information
13.7%
Debt to equity ratio
CN¥649.42m
Debt
| Interest coverage ratio | -3.6x |
| Cash | CN¥3.24b |
| Equity | CN¥4.75b |
| Total liabilities | CN¥1.69b |
| Total assets | CN¥6.45b |
Recent financial health updates
No updates
Recent updates
Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?
Apr 16
Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations
Mar 28Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Feb 27Financial Position Analysis
Short Term Liabilities: 600223's short term assets (CN¥4.6B) exceed its short term liabilities (CN¥1.5B).
Long Term Liabilities: 600223's short term assets (CN¥4.6B) exceed its long term liabilities (CN¥171.3M).
Debt to Equity History and Analysis
Debt Level: 600223 has more cash than its total debt.
Reducing Debt: 600223's debt to equity ratio has reduced from 326.9% to 13.7% over the past 5 years.
Debt Coverage: 600223's debt is well covered by operating cash flow (64.3%).
Interest Coverage: 600223 earns more interest than it pays, so coverage of interest payments is not a concern.